Jin Yang Pharmaceutical Co., Ltd.
KKRX:0073703,630.00
KRW
-165.00
(-4.35%)
ISIN
KR7007370000
Return %
Stock
S&P 500
1Y
-33.88
14.20
3Y
-38.58
81.12
5Y
-52.49
68.34
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Jae-Jun Choi
- Full Time Employees
- 219
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Seoul South Korea
- IPO Date
- Jul 27, 2000
- Website
- jinyangpharm.com
- Similar Companies
- Business
- Jin Yang Pharmaceutical Co., Ltd. is a South Korea-based pharmaceutical manufacturing company engaged in the research, development, production, and distribution of ethical prescription drugs, over-the-counter medications, health functional foods, and medical devices. Founded in 1971 and headquartered in Seoul, South Korea, the company operates across several specialized therapeutic areas and provides contract manufacturing organization (CMO) services to domestic and international pharmaceutical enterprises. The company's primary product portfolio encompasses cardiovascular and circulatory agents, including the antiplatelet therapy Crivix and antihypertensive treatments; endocrine and metabolic disorder medications, including the lipid-lowering combination agent Atovjet and the Dapagreen antidiabetic product family; gastrointestinal treatments, notably the Esazole family of medications for gastroesophageal reflux disease; central nervous system agents, including the neuropathic pain treatment Pregaba and cognitive enhancers such as Jycolin; musculoskeletal, anti-inflammatory, and analgesic medications; respiratory treatments and antihistamines; antibiotic and antibacterial formulations; health functional foods and dietary supplements; and medical devices. Jin Yang Pharmaceutical manufactures its core pharmaceuticals across diverse oral solid dosage forms, including film-coated tablets, capsules, and dry syrups, produced at its cGMP-compliant manufacturing facility located in Wonju, Gangwon Province. In addition to finished pharmaceuticals, the company provides third-party consignment manufacturing, OEM/ODM production services, and formulation technology solutions focused on drug stability and solubility enhancement. In recent developments, Jin Yang Pharmaceutical has accelerated its strategic growth under Chief Executive Officer Choi Jae-joon, surpassing KRW 100 billion in annual revenue in 2024 with a strategic target to achieve KRW 150 billion by 2026. The company has expanded its commercial portfolio through the rapid market rollout and prescription scaling of key combination therapeutics, notably its Atovjet dyslipidemia therapies and Dapagreen antidiabetic line, alongside sustained growth in its flagship Crivix and Esazole product families. Operationally, Jin Yang Pharmaceutical has broadened third-party contract manufacturing operations at its Wonju facility to service an expanding roster of domestic pharmaceutical partners. Globally, the company has reinforced its international footprint through commercial distribution partnerships and product registrations across Southeast Asia, Central Asia, the Middle East, and Latin America, while actively pursuing global out-licensing agreements for proprietary formulation technologies, including its esomeprazole delivery platform. Furthermore, the company continues to progress its clinical R&D pipeline centered on incrementally modified drugs and fixed-dose combinations, including its JY302 antidiabetic combination development program, to strengthen its competitive positioning in chronic disease therapeutics.